Recombinant Human PSMB8, N-His

Description of Recombinant Human PSMB8, N-His

Introduction

Recombinant Human PSMB8, N-His is a protein that plays a crucial role in the cellular process of protein degradation, also known as the ubiquitin-proteasome pathway. This protein is a drug target for various diseases, making it an important molecule in the field of drug discovery and development. In this article, we will discuss the structure, activity, and application of Recombinant Human PSMB8, N-His in detail.

Structure of Recombinant Human PSMB8, N-His

Recombinant Human PSMB8, N-His is a 20S proteasome subunit, which is a part of the 26S proteasome complex. This complex is made up of two 19S regulatory particles and one 20S core particle. The 20S core particle is further composed of four stacked rings, each containing seven different subunits. PSMB8 is one of the seven subunits in the outer rings of the 20S core particle. It has a molecular weight of approximately 25 kDa and consists of 226 amino acids. The N-His tag, which is added during the recombinant protein production process, is used for purification and detection purposes.

Activity of this protein

Recombinant Human PSMB8, N-His is a crucial component of the 20S proteasome complex, which is responsible for the degradation of intracellular proteins. This process involves the tagging of proteins with ubiquitin, a small protein that acts as a “”kiss of death”” for proteins. The tagged proteins are then recognized by the 26S proteasome complex, where they are unfolded and fed into the 20S core particle. The PSMB8 subunit, along with other subunits, forms the active sites within the 20S core particle, where the tagged proteins are cleaved into smaller peptides. These peptides are then further degraded into amino acids, which can be recycled by the cell for the synthesis of new proteins.

Application of Recombinant Human PSMB8, N-His

Recombinant Human PSMB8, N-His has a wide range of applications in the field of drug discovery and development. Due to its role in protein degradation, it is a potential drug target for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In cancer, the proteasome pathway is overactive, leading to the rapid growth and survival of cancer cells. Inhibiting the activity of PSMB8 can disrupt this pathway and lead to the death of cancer cells. Several proteasome inhibitors, such as bortezomib, have been approved by the FDA for the treatment of multiple myeloma and mantle cell lymphoma.

In autoimmune disorders, such as rheumatoid arthritis and lupus, the proteasome pathway is involved in the activation of immune cells and the production of inflammatory cytokines. Inhibiting PSMB8 can suppress the activity of these immune cells and reduce inflammation. This has led to the development of proteasome inhibitors for the treatment of these diseases.

In neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, the accumulation of misfolded proteins is a major contributing factor. These proteins can be degraded by the proteasome pathway, and inhibiting PSMB8 can prevent their accumulation and alleviate the symptoms of these diseases.

In addition to being a drug target, Recombinant Human PSMB8, N-His is also used in research and diagnostic applications. The N-His tag allows for easy purification and detection of the protein, making it a valuable tool in protein studies.

Conclusion

In summary, Recombinant Human PSMB8, N-His is a crucial component of the 20S proteasome complex, which plays a vital role in protein degradation. Its structure and activity make it a potential drug target for various diseases, and it also has applications in research and diagnostics.